Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PHARMACEUTICAL COMPOSITION, COMPRISING AGMATINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR PREVENTION OR TREATMENT OF FRAGILE X SYNDROME
Document Type and Number:
WIPO Patent Application WO/2019/203509
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for prevention or treatment of (psycho)neurologic abnormal behaviors such as bias toward detail-focused processing, cognitive impairment, difficulties with social interaction and communication, hyperactivity, and repetitive behavior, the composition comprising agmatine or a pharmaceutically acceptable salt thereof.

Inventors:
SHIN CHAN YOUNG (KR)
JEON SE JIN (KR)
KIM HEE JIN (KR)
JOO SO HYUN (KR)
Application Number:
PCT/KR2019/004439
Publication Date:
October 24, 2019
Filing Date:
April 12, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KONKUK UNIV GLOCAL IND ACADEMIC COLLABORATION FOUND (KR)
UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV (KR)
NEUROVENTI (KR)
International Classes:
A61K31/155; A23L33/10; A61P25/00
Foreign References:
KR101497932B12015-03-03
US20020065323A12002-05-30
KR20160078956A2016-07-05
Other References:
KIM, J. W.: "Agmatine rescues autistic behaviors in the valproic acid- induced animal model of autism", NEUROPHARMACOLOGY, vol. 113, 2017, pages 71 - 81, XP029832506, DOI: 10.1016/j.neuropharm.2016.09.014
ESNAFOGLU, E.: "Decreased plasma agmatine levels in autistic subjects", JOURNAL OF NEURAL TRANSMISSION, vol. 125, 4 January 2018 (2018-01-04), pages 735 - 740, XP036458279, DOI: 10.1007/s00702-017-1836-2
Attorney, Agent or Firm:
ERUUM & LEEON INTELLECTUAL PROPERTY LAW FIRM (KR)
Download PDF: